Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-TRD2203
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
64Cu-TRD2203 is a radiopharmaceutical agent labeled with the positron-emitting radioisotope copper-64 (64Cu), designed for use in PET/CT imaging. It is being investigated as a diagnostic imaging agent for patients with solid tumors, enabling visualization of tumor lesions through PET scans. The precise molecular target and mechanism of action have not been detailed in available public sources, but as a 64Cu-labeled compound, it likely binds to specific tumor-associated targets to facilitate high-sensitivity detection via PET/CT. The drug is currently under clinical investigation and has not yet received regulatory approval[4].
Beyond the preview
Go deeper on 64Cu-TRD2203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-TRD2203.